The Journal of Clinical Pharmacology

ACCP Practice Statement: "Over-the-Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit"

Retrieved on: 
Tuesday, January 31, 2023

The Practice Statement highlights ACCP formally joining numerous medical organizations in emphasizing the hazards of over-the-counter (OTC) availability of inhaled epinephrine products for the treatment of asthma .

Key Points: 
  • The Practice Statement highlights ACCP formally joining numerous medical organizations in emphasizing the hazards of over-the-counter (OTC) availability of inhaled epinephrine products for the treatment of asthma .
  • Further, ACCP supports the implementation of pharmacist-centered asthma management programs which allow for the provision of asthma-related medication refills and care strategy related to pharmacotherapy.
  • The recommendations made are in the best interest of quality healthcare access and the awareness of inherent dangers of using OTC inhaled epinephrine products for asthma.
  • This statement was published to bring awareness of the ramifications of OTC epinephrine use in asthma and encourages patients to consult with a healthcare professional for appropriate asthma pharmacotherapy management.

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 3, 2022

STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.

Key Points: 
  • STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
  • Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc.
    We are very pleased to welcome Lisa to our board of directors, said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics.
  • Its an exciting time to be joining the board of Cara Therapeutics, said Dr. von Moltke.
  • Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas.

Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Retrieved on: 
Thursday, October 6, 2022

Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.

Key Points: 
  • Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.
  • Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.
  • Alcohol use disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake.
  • Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

Ananda Professional Launches Full-Spectrum Cannabinoid Complex Featuring CBD + CBN

Retrieved on: 
Monday, February 21, 2022

The industry-leading CBD brand that has committed $40 million towards clinical hemp and cannabis research has brought to market a Full Spectrum CBD tincture enhanced with elevated levels of cannabinol (CBN).

Key Points: 
  • The industry-leading CBD brand that has committed $40 million towards clinical hemp and cannabis research has brought to market a Full Spectrum CBD tincture enhanced with elevated levels of cannabinol (CBN).
  • CBD and CBN are two prominent examples of hemp's 140+ naturally occurring cannabinoids.
  • (1)
    Specialists consider CBN the most sedating cannabinoid, promoting better sleep and helping people fall asleep and stay asleep.
  • In the United States, Ananda Professional is the leading pharmacy label for hemp-derived CBD.

Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder

Retrieved on: 
Thursday, January 20, 2022

Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.

Key Points: 
  • Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.
  • However, converging lines of evidence indicate that activation of delta-opioid receptors also contributes to the reinforcing properties of alcohol.
  • Alcohol Use Disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

Retrieved on: 
Monday, November 29, 2021

The PLENITUDE trial is a randomized double-blind phase 2 study assessing the safety and efficacy of QIXLEEF in patients with cancer who have uncontrolled pain.

Key Points: 
  • The PLENITUDE trial is a randomized double-blind phase 2 study assessing the safety and efficacy of QIXLEEF in patients with cancer who have uncontrolled pain.
  • Both studies are conducted across multiple clinical sites located in the United States.
  • Preliminary analysis of the data shows a positive effect on pain relief in QIXLEEFTM-treated patients.
  • Preliminary data from both REBORN1 and PLENITUDEconfirm the safety and pharmacodynamic profile of QIXLEEFreported in the phase I trials.

ACCP's The Journal of Clinical Pharmacology Publishes "Drugs of Abuse" Supplement

Retrieved on: 
Tuesday, August 17, 2021

ASHBURN, Va., Aug. 17, 2021 /PRNewswire/ -- TheAmerican College of Clinical Pharmacology is pleased to announce in the August 2021 supplement in The Journal of Clinical Pharmacology entitled "Drugs of Abuse" , clinical pharmacology experts in substances of abuse bring light to the shadows for clinicians around the globe.

Key Points: 
  • ASHBURN, Va., Aug. 17, 2021 /PRNewswire/ -- TheAmerican College of Clinical Pharmacology is pleased to announce in the August 2021 supplement in The Journal of Clinical Pharmacology entitled "Drugs of Abuse" , clinical pharmacology experts in substances of abuse bring light to the shadows for clinicians around the globe.
  • Covering the full gamut from tobacco, alcohol and natural products all the way through to prescription and illicit drugs, the authors fill in clinical trial gaps with mechanistic insight to allow clinicians to better assess and treat complex patients.
  • We wanted to draw the combined wisdom of international experts in clinical pharmacology to break down the pharmacologic and pharmacokinetic underpinnings for why these effects occur, the time course for these effects and why there is variability in response."
  • ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals.

Opportunistic Journals in Clinical Pharmacology - What Can be Done? | ACCP Policy Statement

Retrieved on: 
Tuesday, May 22, 2018

ASHBURN, Va., May 22, 2018 /PRNewswire/ --The American College of Clinical Pharmacology (ACCP), through its Publications and Public Policy Committees, has issued a Policy Statement on the critical problem of opportunistic journals, often termed "predatory" journals , in the field of clinical pharmacology, with implications for biomedical publications.

Key Points: 
  • ASHBURN, Va., May 22, 2018 /PRNewswire/ --The American College of Clinical Pharmacology (ACCP), through its Publications and Public Policy Committees, has issued a Policy Statement on the critical problem of opportunistic journals, often termed "predatory" journals , in the field of clinical pharmacology, with implications for biomedical publications.
  • Some of the journals have never published an issue, and a common feature is journal titles that resemble titles of existing legitimate journals.
  • The Policy Statement appears in the May, 2018, issues of Clinical Pharmacology in Drug Development and The Journal of Clinical Pharmacology.
  • The ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals.